Analystreport
Agile Therapeutics Inc (NASDAQ: AGRX) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating.
Last agile therapeutics, inc earnings: 11/1 04:15 pm
Check Earnings Report
US:NASDAQ Investor Relations: ir.agiletherapeutics.com/investor-relations
| IMPACT SNAPSHOT | EVENT TIME: | AGRX | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
AGRX alerts
AGRX alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGRX alerts
High impacting Agile Therapeutics, Inc news events
Weekly update
A roundup of the hottest topics
AGRX
NEWS
NEWS
- Wainwright bullish on Agile Therapeutics, sees 270% upside [Seeking Alpha][Seeking Alpha]
- Agile Therapeutics Inc (NASDAQ: AGRX) is now covered by analysts at Maxim Group. They set a "buy" rating and a $3.00 price target on the stock.[MarketBeat]
- Agile Therapeutics files for $100M mixed shelf offering [Seeking Alpha][Seeking Alpha]
- Agile Therapeutics Reports Third Quarter 2018 Financial Results[GlobeNewswire]
- Agile Therapeutics, Inc. Presents Additional Analyses of AG200-15 (Twirla®) Phase 3 SECURE Study Results at the 2018 North American Forum on Family Planning (NAFFP)[GlobeNewswire]
- More
AGRX
SEC Filings
SEC Filings
- 11/15/18 - Form EFFECT
- 11/2/18 - Form S-8
- 11/2/18 - Form S-3
- AGRX's page on the SEC website
- More